Janmet XR 50 mg+500 mg (Tablet (Extended Release))

Indications

• Adjunct to diet and exercise for type 2 diabetes mellitus
• Improving glycemic control in adults
• Limitations of use in type 1 diabetes
• Limitations of use in diabetic ketoacidosis
• Not studied in patients with a history of pancreatitis

Pharmacology

• Combines sitagliptin and metformin
• Antihyperglycemic agents
• Complementary mechanisms of action
• DPP-4 inhibitor
• Biguanide class

Dosage & Administration

• Individualized dosage
• Maximum recommended daily dose
• Twice daily with meals
• Gradual dose escalation
• Starting dose based on patient's current regimen

Interaction

• Cationic drugs caution
• Phenprocoumon interaction
• Levothyroxine interaction

Contraindications

• Renal disease or dysfunction
• Metabolic acidosis
• Hypersensitivity reaction
• Contrast materials interaction

Side Effects

• Common adverse reactions
• Hypoglycemia
• Nasopharyngitis
• Diarrhea
• Headache

Pregnancy & Lactation

• Pregnancy Category B
• No adequate studies in pregnant women
• Caution in nursing women

Precautions & Warnings

• Lactic Acidosis risk factors
• Thyroid-stimulating hormone monitoring
• Vitamin B12 level monitoring
• Hepatic disease caution
• Renal function assessment
• Acute pancreatitis risk
• Hematologic parameter monitoring
• Allergic and hypersensitivity reactions
• Macrovascular risk reduction

Overdose Effects

• Supportive measures for sitagliptin overdose
• Dialyzable nature of sitagliptin
• Supportive therapy for metformin overdose
• Dialyzable nature of metformin
• Pancreatitis risk in metformin overdose

Therapeutic Class

• Oral hypoglycemic preparations

Storage Conditions

• Store below 25°C
• Dry place away from light
• Keep out of reach of children
• Do not use after expiry date
• Dispensed only on prescription

Related Brands

• Sitacret-M 50 mg+500 mg (Tablet) - renata-limited
• Sitafit 50 mg+500 mg (Tablet) - team-pharmaceuticals-ltd